What is the standard treatment regimen for Hodgkin's Lymphoma in high-risk patients?

The standard treatment regimen for Hodgkin's Lymphoma in high-risk patients typically involves the ABVD regimen, which includes Adriamycin (Doxorubicin), Bleomycin, Vinblastine, and Dacarbazine. High-risk patients often require more intensive therapy to enhance their chances of remission and minimize the potential for relapse, which is why the ABVD regimen is widely used in this context.

While the AV-PC regimen includes Adriamycin, Vincristine, Prednisone, and Cyclophosphamide, it is not the standard treatment for Hodgkin's Lymphoma. Unlike ABVD, which has proven efficacy and is a cornerstone in the treatment of Hodgkin's Lymphoma, AV-PC lacks supporting evidence as a first-line treatment option specifically for Hodgkin's in high-risk patients.

Additionally, the CHOP regimen is often associated with Non-Hodgkin's Lymphoma and is not typically utilized for Hodgkin’s Lymphoma treatment. The ICE regimen is primarily used as salvage therapy for patients who have relapsed and not as a first-line treatment for initial cases.

The preferred choice remains ABVD due to its effectiveness and established safety profile in managing Hodgkin's Lymphoma in patients categorized as